Literature DB >> 10913376

Cholesterol modulates vascular reactivity to endothelin-1 by stimulating a pro-inflammatory pathway.

D Paris1, T Town, J Humphrey, K Yokota, M Mullan.   

Abstract

Hypercholesterolemia (HC) is associated with coronary endothelial dysfunction and increased circulating levels of endothelin-1. We show that pre-treatment of intact rat aortic rings with cholesterol synergistically enhances the vasoconstriction induced by endothelin-1 suggesting that elevated levels of cholesterol may predispose to hypertension by modulating the vascular reactivity to endogenous vasoconstrictors. Moreover, we report that SB202190, a selective inhibitor of p38 MAPK, and PD98059 an inhibitor of MEK1/2 are able to abolish the vasoactive properties of cholesterol. MK-886, an inhibitor of 5-lipoxygenase is inefficient at blocking the vasoactive properties of cholesterol whereas NS-398, a selective inhibitor of cyclooxygenase-2 (COX-2) completely abolishes cholesterol-induced vasoconstriction. In intact rat aortae, cholesterol stimulates prostaglandin E(2) and prostaglandin F(2 alpha) production, an effect that can be completely prevented by inhibiting p38 MAPK, or COX-2. In vitro, cholesterol appears to stimulate a similar pro-inflammatory pathway in human cerebrovascular smooth muscle cells. Disruption of the MAPK/COX-2 pathway may represent a valuable therapy to block the hypertension associated with HC, as well as the development of atherosclerosis. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10913376     DOI: 10.1006/bbrc.2000.3174

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Transforming growth factor-beta(1) expression in dilated cardiomyopathy.

Authors:  J E Sanderson; K B Lai; I O Shum; S Wei; L T Chow
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

2.  Idiopathic dilated cardiomyopathy: lack of association with haemochromatosis gene in the CARDIGENE study.

Authors:  G Hetet; B Grandchamp; C Bouchier; V Nicaud; L Tiret; G Roizès; M Desnos; K Schwartz; R Dorent; M Komajda
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

3.  Contrast enhanced magnetic resonance angiography and pulmonary venous anomalies.

Authors:  F Godart; S Willoteaux; C Rey; B Cocheteux; C Francart; J P Beregi
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

4.  Effects of cardiac resynchronisation on maximal and submaximal exercise performance in advanced heart failure patients with conduction abnormality.

Authors:  D Birnie; L P Soucie; S Smith; A S Tang
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

5.  Reciprocal increase of circulating interleukin-10 and interleukin-6 in patients with acute myocardial infarction.

Authors:  N Kotajima; T Kimura; T Kanda; A Kuwabara; Y Fukumura; M Murakami; I Kobayashi
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

6.  Percutaneous aortic valve replacement: will we get there?

Authors:  Y Boudjemline; P Bonhoeffer
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

7.  Tetrahydrobiopterin attenuates cholesterol induced coronary hyperreactivity to endothelin.

Authors:  S Verma; A S Dumont; A Maitland
Journal:  Heart       Date:  2001-12       Impact factor: 5.994

Review 8.  Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease.

Authors:  Cynthia M Carlsson
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

9.  Reduced contribution of endothelin to the regulation of systemic and pulmonary vascular tone in severe familial hypercholesterolaemia.

Authors:  Shawn B Bender; Vincent J de Beer; Darla L Tharp; Elza D van Deel; Douglas K Bowles; Dirk J Duncker; M Harold Laughlin; Daphne Merkus
Journal:  J Physiol       Date:  2014-01-13       Impact factor: 5.182

10.  Inflammation-induced atherosclerosis as a target for prevention of cardiovascular diseases from early life.

Authors:  Roya Kelishadi
Journal:  Open Cardiovasc Med J       Date:  2010-02-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.